BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 20868587)

  • 1. Switching to adalimumab is effective in a case of neuro-Behcet's disease refractory to infliximab.
    Leccese P; D'Angelo S; Angela P; Coniglio G; Olivieri I
    Clin Exp Rheumatol; 2010; 28(4 Suppl 60):S102. PubMed ID: 20868587
    [No Abstract]   [Full Text] [Related]  

  • 2. Efficacy of infliximab and adalimumab in the treatment of a patient with severe neuro-Behçet's disease.
    Belzunegui J; López L; Paniagua I; Intxausti JJ; Maíz O
    Clin Exp Rheumatol; 2008; 26(4 Suppl 50):S133-4. PubMed ID: 19026138
    [No Abstract]   [Full Text] [Related]  

  • 3. Successful treatment of recalcitrant genital ulcers of Behçet's disease with adalimumab after failure of infliximab and etanercept.
    Olivieri I; D' Angelo S; Padula A; Leccese P; Mennillo GA
    Clin Exp Rheumatol; 2009; 27(2 Suppl 53):S112. PubMed ID: 19796550
    [No Abstract]   [Full Text] [Related]  

  • 4. Adalimumab: a new modality for Behçet's disease?
    van Laar JA; Missotten T; van Daele PL; Jamnitski A; Baarsma GS; van Hagen PM
    Ann Rheum Dis; 2007 Apr; 66(4):565-6. PubMed ID: 17124248
    [No Abstract]   [Full Text] [Related]  

  • 5. Successful switching to adalimumab in an infliximab-allergic patient with severe Behçet disease-related uveitis.
    Takase K; Ohno S; Ideguchi H; Uchio E; Takeno M; Ishigatsubo Y
    Rheumatol Int; 2011 Feb; 31(2):243-5. PubMed ID: 19816689
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Successful treatment of leg ulcers in Behçet's disease using adalimumab plus methotrexate after the failure of infliximab.
    Atzeni F; Leccese P; D'Angelo S; Sarzi-Puttini P; Olivieri I
    Clin Exp Rheumatol; 2010; 28(4 Suppl 60):S94. PubMed ID: 20868581
    [No Abstract]   [Full Text] [Related]  

  • 7. Successful treatment of refractory neuro-Behcet's disease with infliximab: a case report to show its efficacy by magnetic resonance imaging, transcranial magnetic stimulation and cytokine profile.
    Fujikawa K; Aratake K; Kawakami A; Aramaki T; Iwanaga N; Izumi Y; Arima K; Kamachi M; Tamai M; Huang M; Nakamura H; Nishiura Y; Origuchi T; Ida H; Eguchi K
    Ann Rheum Dis; 2007 Jan; 66(1):136-7. PubMed ID: 17178762
    [No Abstract]   [Full Text] [Related]  

  • 8. Real-world efficacy of adalimumab and infliximab for refractory intestinal Behçet's disease.
    Sugimura N; Mizoshita T; Sugiyama T; Togawa S; Miyaki T; Suzuki T; Tanida S; Kataoka H; Sasaki M
    Dig Liver Dis; 2019 Jul; 51(7):967-971. PubMed ID: 30872086
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of switching to adalimumab in a patient with refractory uveitis of Behçet's disease to infliximab.
    Leccese P; Latanza L; D'Angelo S; Padula A; Olivieri I
    Clin Exp Rheumatol; 2011; 29(4 Suppl 67):S93. PubMed ID: 21813069
    [No Abstract]   [Full Text] [Related]  

  • 10. Adalimumab for sight-threatening uveitis in Behçet's disease.
    Mushtaq B; Saeed T; Situnayake RD; Murray PI
    Eye (Lond); 2007 Jun; 21(6):824-5. PubMed ID: 16601736
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of infliximab on refractory uveitis in Behcet's disease.
    Sayarlioglu M; Cinal A; Topcu N; Demirok A
    Ann Pharmacother; 2004 May; 38(5):901-2. PubMed ID: 15010522
    [No Abstract]   [Full Text] [Related]  

  • 12. Successful treatment of genital ulcers with infliximab in Behcet's disease.
    Haugeberg G; Velken M; Johnsen V
    Ann Rheum Dis; 2004 Jun; 63(6):744-5. PubMed ID: 15140785
    [No Abstract]   [Full Text] [Related]  

  • 13. Intestinal Behçet's disease: maintenance of remission with adalimumab monotherapy.
    Ariyachaipanich A; Berkelhammer C; Nicola H
    Inflamm Bowel Dis; 2009 Dec; 15(12):1769-71. PubMed ID: 19177427
    [No Abstract]   [Full Text] [Related]  

  • 14. Anti-Tumor Necrosis Factor Therapy in Intestinal Behçet's Disease.
    Park J; Cheon JH
    Gut Liver; 2018 Nov; 12(6):623-632. PubMed ID: 29788675
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intra-articular anti-tumor necrosis factor alpha antibody in recalcitrant arthritis of Behçet's disease.
    Andonopoulos AP; Meimaris N; Daoussis D; Bounas A; Yiannopoulos G
    Clin Exp Rheumatol; 2003; 21(4 Suppl 30):S57-8. PubMed ID: 14727465
    [No Abstract]   [Full Text] [Related]  

  • 16. [Treatment of severe Behçet's disease with anti-TNF-alpha: infliximab. A case report].
    Andreu M; Ramanoelina J; Fajnkuchen F; Mouthon L; Cohen P; Laroche L; Guillevin L
    Ann Med Interne (Paris); 2002 Oct; 153(6):414-5. PubMed ID: 12486393
    [No Abstract]   [Full Text] [Related]  

  • 17. Infliximab for the treatment of Neuro-Behçet's disease: a case series and review of the literature.
    Pipitone N; Olivieri I; Padula A; D'angelo S; Nigro A; Zuccoli G; Boiardi L; Salvarani C
    Arthritis Rheum; 2008 Feb; 59(2):285-90. PubMed ID: 18240181
    [No Abstract]   [Full Text] [Related]  

  • 18. Infliximab in refractory uveitis due to Behçet's disease.
    Wechsler B; Sablé-Fourtassou R; Bodaghi B; Huong DL; Cassoux N; Badelon I; Fain O; LeHoang P; Piette JC
    Clin Exp Rheumatol; 2004; 22(4 Suppl 34):S14-6. PubMed ID: 15515776
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of adalimumab in patients with Behçet's disease unsuccessfully treated with infliximab.
    Olivieri I; Leccese P; D'Angelo S; Padula A; Nigro A; Palazzi C; Coniglio G; Latanza L
    Clin Exp Rheumatol; 2011; 29(4 Suppl 67):S54-7. PubMed ID: 21968237
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The efficacy of a single dose of infliximab in the treatment of Behçet's disease uveitis.
    Arayssi T; Hamra R; Homeidan F; Uthman I; Awwad ST; Mroue K; Mansour W; Bashshur ZF
    Clin Exp Rheumatol; 2005; 23(3):427. PubMed ID: 15971438
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 12.